文献速递血液净化与透析水电解质与酸碱

维持性透析患者的连续血糖监测评估

Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis.
PubMed 文献 · J Am Soc Nephrol · 2025-03-21

这项前瞻性社区队列研究纳入420例维持性透析患者,使用Dexcom G6 Pro连续血糖监测约10天。结果显示,无论是否合并糖尿病,高血糖和低血糖均常见且可能临床不明显;接受治疗的糖尿病患者很少达到当代基于CGM的治疗目标。

要点

  • 维持性透析患者中CGM常发现临床不明显的高血糖和低血糖。
  • 接受治疗的糖尿病患者仅22%达到TIR≥70%。
  • 无糖尿病患者中腹膜透析者平均血糖高于血液透析者。

核心结论

  • 维持性透析患者中CGM常识别出临床不明显的高血糖和低血糖。
  • 接受治疗的糖尿病患者很少达到当代基于CGM的治疗目标。

研究设计与样本

  • 前瞻性社区队列研究,纳入420例维持性透析患者,其中糖尿病患者263例(88例未接受降糖药物治疗),无糖尿病患者157例,55例使用腹膜透析。
  • 每位参与者佩戴Dexcom G6 Pro CGM约10天。

主要发现

  • 无糖尿病患者中,腹膜透析者平均血糖高于血液透析者(141 vs 121 mg/dl,P < 0.001)。
  • 未接受治疗的糖尿病患者平均血糖162 mg/dl,平均TIR 71%,仅64%达到TIR≥70%,平均HbA1c 5.7%。
  • 接受治疗的糖尿病患者平均血糖214 mg/dl,平均TIR 43%,仅22%达到TIR≥70%,平均HbA1c 7.0%。
  • 共观察到714次持续性低血糖事件,无糖尿病者发生率最高。
  • 年龄、透析龄、胰岛素使用、HbA1c和血清白蛋白与平均血糖或低血糖显著相关。

关键数值与推荐

  • TIR定义为70–180 mg/dl。
  • 低血糖事件定义为持续性<70 mg/dl。

临床怎么用

  • 在维持性透析患者中可考虑使用CGM识别临床不明显的高血糖和低血糖。
  • 对接受治疗的糖尿病患者应关注基于CGM的治疗目标达标情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. BACKGROUND: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. METHODS: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained <70 mg/dl). RESULTS: We enrolled 420 demographically diverse participants, including 263 with diabetes (of whom 88 were untreated with glucose-lowering medications) and 157 without diabetes. Peritoneal dialysis (PD) was used by 55 participants. Outcomes varied by diabetes status and dialysis modality. Among participants without diabetes, mean blood glucose was higher with PD versus hemodialysis (141 versus 121 mg/dl, P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. CONCLUSIONS: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. de Boer IH, Anderson LD, Ashford NK, et al. Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis. J Am Soc Nephrol. 2025. PMID: 40117214. doi:10.1681/ASN.0000000693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。